Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

about

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

Item

http://www.wikidata.org/entity/Q53035901

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@en

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@nl

type

Item

label

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@en

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@nl

prefLabel

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@en

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@nl

P1476

Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.

@en

P2093

Ronald van Vollenhoven

http://www.w3.org/2001/XMLSchema#string

P2860

Type I interferon blockade in systemic lupus erythematosus: where do we stand?

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

The type I interferon system in systemic lupus erythematosus.

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus.

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

P304

1899-1901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1136/ANNRHEUMDIS-2016-209345

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27329393

http://www.w3.org/2001/XMLSchema#string